Breaking Finance News

A statement released earlier today by Mizuho Securities about Teva Pharmaceutical (NYSE:TEVA) bumps down the target price to $27.00

Boasting a price of $32.25, Teva Pharmaceutical (NYSE:TEVA) traded -0.19% lower on the day. With the last stock price close down -25.01% from the two hundred day average, compared with the S&P 500 Index which has increased 0.06% over the date range. Teva Pharmaceutical has recorded a 50-day average of $34.51 and a two hundred day average of $42.93. Volume of trade was up over the average, with 13,823,830 shares of TEVA changing hands over the typical 10,543,400

Mizuho Securities bumped down the target of Teva Pharmaceutical (NYSE:TEVA) to $27.00 stating a potential downside of -0.16%.

Performance Chart

Teva Pharmaceutical (NYSE:TEVA)

With a total market value of $0, Teva Pharmaceutical has price-earnings ratio of 18.73 with a one year low of $31.90 and a one year high of $59.35 .

A total of 22 brokerages have issued a ratings update on Teva Pharmaceutical. Ten analysts rating the company a strong buy, nine analysts rating the company a buy, six analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $72.82.

General Information About Teva Pharmaceutical (NYSE:TEVA)

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.